Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Consolidated Net Income (2019 - 2026)

Revolution Medicines has reported Consolidated Net Income over the past 7 years, most recently at -$364.9 million for Q4 2025.

  • For Q4 2025, Consolidated Net Income fell 86.88% year-over-year to -$364.9 million; the TTM value through Dec 2025 reached -$1.1 billion, down 88.31%, while the annual FY2025 figure was -$1.1 billion, 88.31% down from the prior year.
  • Consolidated Net Income for Q4 2025 was -$364.9 million at Revolution Medicines, down from -$305.2 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at -$37.2 million in Q1 2021 and troughed at -$364.9 million in Q4 2025.
  • A 5-year average of -$130.4 million and a median of -$103.4 million in 2023 define the central range for Consolidated Net Income.
  • Biggest five-year swings in Consolidated Net Income: dropped 7.31% in 2022 and later crashed 192.58% in 2023.
  • Year by year, Consolidated Net Income stood at -$52.7 million in 2021, then dropped by 7.31% to -$56.5 million in 2022, then plummeted by 192.58% to -$165.4 million in 2023, then dropped by 18.06% to -$195.3 million in 2024, then plummeted by 86.88% to -$364.9 million in 2025.
  • Business Quant data shows Consolidated Net Income for RVMD at -$364.9 million in Q4 2025, -$305.2 million in Q3 2025, and -$247.8 million in Q2 2025.